BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...
European Space Agency (ESA) astronaut Thomas Pesquet removes the Protein Crystallization Facility hardware from an incubator ...
Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, ...
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...
Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.
Zacks Investment Research on MSN
Can the US launch of NVO's Wegovy pill reignite momentum in 2026?
Shares of Novo Nordisk NVO jumped 5.2% on Monday and about 4% in the pre-market hours today as investors cheered the U.S.
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) ...
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback